June 19, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score.
Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
(No summary available.)
Read more →The DEA placed 3-methoxyphencyclidine, a dissociative anesthetic with no accepted medical use, into Schedule I, impacting any potential research involving this substance and clarifying its legal status separate from cannabis.
Read more →Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
(No summary available.)
Read more →Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
(No summary available.)
Read more →Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I
The DEA placed 4-fluoroamphetamine into Schedule I, potentially impacting research access and clinical use should similar scheduling actions occur for cannabinoids or related compounds.
Read more →Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
The DEA temporarily placed bromazolam, a benzodiazepine sometimes found as an adulterant in illicit cannabis products, into Schedule I, impacting its legality and clinical use.
Read more →Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
(No summary available.)
Read more →Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I
(No summary available.)
Read more →Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
The DEA placed synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting clinical practice and legal considerations regarding cannabinoid products.
Read more →Exempt Chemical Preparations Under the Controlled Substances Act
(No summary available.)
Read more →Schedules of Controlled Substances: Temporary Placement of Seven Benzimidazole-Opioids in Schedule I
(No summary available.)
Read more →Digest-Level Clinical Commentary
These regulatory actions predominantly address synthetic cannabinoids, novel benzodiazepines, and emerging opioid analogs rather than cannabis itself, reflecting the DEA’s focus on designer drugs that often pose greater acute toxicity and addiction liability than traditional cannabis. As a cannabis medicine practitioner, I interpret this pattern as regulatory clarity that distinguishes cannabis from the increasingly dangerous synthetic compounds circulating in unregulated markets, which helps inform evidence-based conversations with patients about relative risk profiles. The proliferation of these scheduling actions underscores why cannabis’s Schedule I status appears increasingly incongruous with its clinical applications and safety profile relative to these newly scheduled substances, though this observation does not diminish the legitimate public health concerns driving these enforcement priorities.
Clinical Perspective on Controlled Substance Scheduling Trends The regulatory actions documented here reflect an ongoing effort to address the proliferation of synthetic drugs designed to circumvent existing controlled substance laws through minor chemical modifications. These substances, primarily synthetic cannabinoids, benzodiazepines, cathinones, opioids, and nitazenes, represent a persistent public health challenge characterized by rapid innovation in clandestine chemistry that outpaces formal scheduling procedures. From a clinical standpoint, the pattern of temporary placements followed by permanent scheduling underscores the lag between emergence of novel psychoactive substances and their regulatory control, during which clinicians encounter increasing numbers of patients with toxidromes from unfamiliar compounds that lack established safety or efficacy data.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
